BTRX-335140

BTRX-335140

BTRX-335140 (also known as BTRX-140, KOR antagonist 2, or Compound 2) is a novel, orally available, and selective kappa opioid receptor (KOR) antagonist that is being developed by BlackThorn Therapeutics for the treatment of neurobehavioral disorders.

Chemistry

BTRX-335140 is a small molecule that selectively antagonizes the kappa opioid receptor. It is structurally distinct from other known KOR antagonists. The chemical structure of BTRX-335140 is represented by the following chemical formula: C22H23N5O.

Pharmacology

BTRX-335140 acts as an antagonist at the kappa opioid receptor, a type of G protein-coupled receptor (GPCR) that is activated by the endogenous opioid dynorphin. By blocking the activity of dynorphin at the KOR, BTRX-335140 is thought to alleviate symptoms associated with neurobehavioral disorders.

Clinical Development

BTRX-335140 is currently in clinical development for the treatment of neurobehavioral disorders. In preclinical studies, BTRX-335140 demonstrated a favorable safety profile and efficacy in models of depression and anxiety. The drug is currently being evaluated in Phase 2 clinical trials.

Potential Therapeutic Applications

The kappa opioid receptor has been implicated in a variety of neurobehavioral disorders, including depression, anxiety disorders, and substance use disorders. By antagonizing the KOR, BTRX-335140 may have therapeutic potential in these conditions.

See Also

• Kappa Opioid Receptor
• BlackThorn Therapeutics
• Neurobehavioral Disorders